Exelixis, Inc.
NASDAQ: EXEL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael Morrissey
- Employees
- 1,147
- Headquarters
- Alameda, United States
- IPO year
- 2000
- Market cap
- $13.0B
- Website
- https://www.exelixis.com
Loading EXEL…
Loading profile data…Frequently asked questions about EXEL
What does Exelixis, Inc. (EXEL) do?
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinom...
Where does EXEL trade?
Exelixis, Inc. (EXEL) trades on the NASDAQ Global Select.
What sector is EXEL in?
Exelixis, Inc. (EXEL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Exelixis, Inc.?
Michael Morrissey is the chief executive officer of Exelixis, Inc. (EXEL).
Where is Exelixis, Inc. headquartered?
Exelixis, Inc. is headquartered in United States.
Does EXEL pay a dividend?
Exelixis, Inc. (EXEL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EXEL go public?
Exelixis, Inc. (EXEL) completed its initial public offering in 2000.